Entities / Entity
onasemnogene abeparvovec.
gene therapy product
- Reports this week
- 0
- Active events
- 0
- Connections
- 6
What's happening
No events on record for onasemnogene abeparvovec yet.
No events began in the chosen period. Widen it, or reset.
Around onasemnogene abeparvovec this week
News at the entities that move onasemnogene abeparvovec most-
Novartis StructuralBristol-Myers Squibb paused clinical trials following clinical setbacks reported by Novartis.Moves onasemnogene abeparvovec
-
European Commission StructuralThe European Commission will ask Germany, Italy, and Sweden for more effort regarding EU commitments.Moves onasemnogene abeparvovec
Connections
The 3 strongest of 6, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Novartis Structural
Novartis is the company that develops, licenses, and brings the onasemnogene abeparvovec gene therapy product to market.
-
SMA Structural
Company SMA develops and offers the product onasemnogene abeparvovec as a treatment for SMA.
-
European Commission Structural
The European Commission granted regulatory approval for the product onasemnogene abeparvovec.